Condition: Non-Small Cell Lung Cancer · Sponsor: Assistance Publique - Hôpitaux de Paris
The main objective is to identify and assess the predictive value of ageing and senescence biomarkers (methylome, telomeres, inflammageing) and senescent cells in tissues to improve prognosis assessment older patients with locally or locally-advanced Non-Small Cell Lung Cancer (NSCLC).
This description comes directly from the study's public registry record.
Florence CANOUÏ-POITRINE, PhD · 01 49 81 36 74 · florence.canoui-poitrine@aphp.fr
Adèle BELLINO, Project advisor · 01 71 76 07 57 · adele.bellino@aphp.fr
Always discuss trial participation with your own doctor first.
| Henri Mondor Hospital | Créteil, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06923618